FengYe Ph.D.

Associate

San Diego + 1.858.314.1175

Feng Ye's practice includes representing pharmaceutical and biotechnology companies on the procurement and protection of intellectual property. He develops and manages U.S. and foreign patent portfolios for clients and coordinates strategies to meet clients' IP needs and business goals. Feng drafts and prosecutes patent applications in diagnostics, antibodies and other therapeutic proteins, therapeutic peptides, antibody drug conjugates, stem cells, personalized medicine, pharmaceuticals, and microbiology, among others.

Feng also counsels client on issues including patentability, validity, enforceability, infringement, and freedom-to-operate and has extensive experience conducting due diligence research and analysis for business merger and acquisition, investment, and public stock offerings.

Prior to joining Jones Day in 2016, Feng worked as director of product development and protein science at Allele Biotechnology and Pharmaceuticals. While at Allele Biotech, he led the nano-antibody development team and several stem cell differentiation programs. Before joining Allele, Feng worked as a research scientist and completed his post-doctoral fellowship in the Department of Medicine at the University of California, San Diego.

Feng has coauthored more than 30 peer-reviewed scientific publications, many of them in highly respected journals such as Cell, Blood, Nature, and The Journal of Cell Biology. He was the recipient of the 2014 Kenneth M. Brinkhous Young Investigator Prize from the American Heart Association and as a co-principal investigator, Feng received three merit-based SBIR awards from the National Institute of Health.

Experience

  • Milliken & Company acquires Borchers from The Jordan CompanyJones Day advised Milliken & Company in its acquisition of Borchers Group Limited, a global specialty chemicals company known for its innovative high-performance coating additives and specialty catalyst solutions, from The Jordan Company, L.P.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Celgene acquires Juno Therapeutics for $9 billionOn behalf of Celgene Corporation, Jones Day conducted a large-scale intellectual property due diligence review and evaluation of matters related to its definitive merger agreement and acquisition of Juno Therapeutics for approximately $9 billion, including Juno’s technology related to CAR-T and TCR cellular immunotherapeutics for use in oncology and other indications.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.